Karen Kaiser

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5530469/publications.pdf

Version: 2024-02-01

759190 752679 31 420 12 20 citations h-index g-index papers 31 31 31 846 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis. Lung, 2016, 194, 227-234.	3.3	82
2	An evaluation of health-related quality of life in patients with systemic lupus erythematosus using PROMIS and Neuro-QoL. Clinical Rheumatology, 2017, 36, 555-562.	2.2	42
3	A Comprehensive Conceptual Model of the Experience of Chronic Itch in Adults. American Journal of Clinical Dermatology, 2018, 19, 759-769.	6.7	40
4	Development, Validation, and Interpretation of the PROMIS Itch Questionnaire: A Patient-Reported Outcome Measure for the Quality of Life Impact of Itch. Journal of Investigative Dermatology, 2020, 140, 986-994.e6.	0.7	22
5	Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. PLoS ONE, 2020, 15, e0237497.	2.5	21
6	Important and relevant symptoms including pain concerns in hepatocellular carcinoma (HCC): a patient interview study. Supportive Care in Cancer, 2014, 22, 919-926.	2.2	20
7	Cancer experiences and health-related quality of life among racial and ethnic minority survivors of young adult cancer: a mixed methods study. Supportive Care in Cancer, 2016, 24, 4861-4870.	2.2	19
8	Development of a shared decision-making tool to assist patients and clinicians with decisions on oral anticoagulant treatment for atrial fibrillation. Current Medical Research and Opinion, 2015, 31, 2261-2272.	1.9	17
9	Health-related quality of life among women with ductal carcinoma <i>in situ</i> or early invasive breast cancer: validation of the FACT-B (version 4). Expert Review of Quality of Life in Cancer Care, 2016, 1, 99-109.	0.6	17
10	Importance and Relevance of Pulmonary Symptoms Among Patients Receiving Second- and Third-Line Treatment for Advanced Non–Small-Cell Lung Cancer: Support for the Content Validity of the 4-Item Pulmonary Symptom Index. Clinical Lung Cancer, 2013, 14, 245-253.	2.6	14
11	Awareness of preventive medication among women at high risk for breast cancer and their willingness to consider transdermal or oral tamoxifen: a focus group study. BMC Cancer, 2015, 15, 878.	2.6	13
12	<p>Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) Medication Adherence Scale (PMAS)</p> . Patient Preference and Adherence, 2020, Volume 14, 971-983.	1.8	13
13	Content validity of the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18). Gynecologic Oncology, 2015, 136, 317-322.	1.4	12
14	Development and validation of the functional assessment of cancer therapy–antiangiogenesis subscale. Cancer Medicine, 2015, 4, 690-698.	2.8	11
15	Radiation Oncologists' Role in End-of-Life Care: A Perspective From Medical Oncologists. Practical Radiation Oncology, 2019, 9, 362-370.	2.1	11
16	Medical oncologist perspectives on palliative care reveal physician-centered barriers to early integration. Annals of Palliative Medicine, 2020, 9, 2800-2808.	1.2	11
17	Validation of the Functional Assessment of Cancer Therapy-Breast (FACT-B) quality of life instrument Journal of Clinical Oncology, 2015, 33, e17753-e17753.	1.6	10
18	Neuropathy experienced by colorectal cancer patients receiving oxaliplatin: A qualitative study to validate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity scale. World Journal of Gastrointestinal Oncology, 2020, 12, 205-218.	2.0	10

#	Article	IF	Citations
19	Black Womenâ∈™s Awareness of Breast Cancer Disparity and Perceptions of the Causes of Disparity. Journal of Community Health, 2013, 38, 766-772.	3.8	9
20	What does risk of future cancer mean to breast cancer patients?. Breast Cancer Research and Treatment, 2019, 175, 579-584.	2.5	9
21	<p>Assessing Preferences for Rare Disease Treatment: Qualitative Development of the Paroxysmal Nocturnal Hemoglobinuria Patient Preference Questionnaire (PNH-PPQ©)</p> . Patient Preference and Adherence, 2020, Volume 14, 705-715.	1.8	5
22	Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index. Neuroendocrinology, 2021, 111, 850-862.	2.5	4
23	Psychometric properties of a brief, clinically relevant measure of pain in patients with hepatocellular carcinoma. Quality of Life Research, 2014, 23, 2447-2455.	3.1	3
24	Pain and other symptoms in patients with hepatocellular carcinoma (HCC): A qualitative analysis Journal of Clinical Oncology, 2013, 31, e15187-e15187.	1.6	2
25	Breast cancer patients' risk perceptions and treatment values following surgical consult Journal of Clinical Oncology, 2013, 31, 36-36.	1.6	1
26	Barriers to early integration of palliative care: A qualitative analysis of medical oncologist attitudes and practice patterns Journal of Clinical Oncology, 2018, 36, e22191-e22191.	1.6	1
27	Optimizing a Behavioral Sleep Intervention for Gynecologic Cancer Survivors: Study Design and Protocol. Frontiers in Neuroscience, 2022, 16, 818718.	2.8	1
28	Pulmonary symptoms and their importance to patients with non-small cell lung cancer undergoing second- and third-line chemotherapy Journal of Clinical Oncology, 2012, 30, 9056-9056.	1.6	0
29	Key concerns and symptoms of patients undergoing second- and third-line treatment for non-small cell lung cancer: Findings from a patient interview study Journal of Clinical Oncology, 2012, 30, 63-63.	1.6	0
30	Development and validation of the functional assessment of cancer therapy: Antiangiogenesis (FACT-AntiA) Journal of Clinical Oncology, 2013, 31, e20527-e20527.	1.6	0
31	Breast cancer patients' risk perceptions and treatment values following surgical consult Journal of Clinical Oncology, 2013, 31, e11572-e11572.	1.6	O